ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1637803
This article is part of the Research TopicCommunity Series in Immune Responses Against Tumors - From the Bench to the Bedside: Volume IIView all 7 articles
Elevated serum total Immunoglobulin E is associated with an increased risk of lung cancer: a retrospective study
Provisionally accepted
- 1Department of Gerontology and Geriatrics, The First Hospital of China Medical University, Shenyang, China
- 2The First Affiliated Hospital of China Medical University, Shenyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: This study investigated the correlation between serum total IgE levels and the risk of lung cancer using univariate and multivariate logistic regression analysis. Methods: This cross-sectional retrospective cohort study included clinical and laboratory data from 675 lung cancer patients and 1,193 healthy controls. Results: The lung cancer patients showed significantly higher serum total IgE levels compared to healthy individuals, with 47.9% of patients having IgE levels >100 IU/ml (P < 0.01). Higher serum total IgE levels (>100 IU/ml) were significantly associated with increased risk of lung cancer (OR=1.534, 95% CI: 1.203-1.957; P < 0.001). Multivariate logistic regression analysis results showed that age ≥65 years (OR=4.775, 95% CI = 3.478–6.555; P <0.001), smoking history (OR=1.719, 95% CI = 1.198–2.466; P =0.003), and an elevated lymphocyte-to-monocyte ratio (LMR) (OR=0.777, 95% CI = 0.678–0.890; P <0.001) were independent risk factors for lung cancer development in subjects with serum total IgE levels >100 IU/ml. The higher the serum total IgE level, the higher the T stage, N stage, M stage and the later the tumor clinical stage (all P <0.001). Survival analysis did not show statistically significant differences in the median progression-free survival (PFS) (P>0.05) or overall survival (OS) (P>0.05) among advanced lung cancer patients with different IgE levels (high and low). Conclusion: Lung cancer patients demonstrated elevated serum total IgE levels. Higher serum IgE levels were significantly associated with an increased risk of lung cancer. Therefore, serum total IgE level is a potential diagnostic biomarker for lung cancer. Moreover, IgE and its related allergic immune responses offer potential as innovative therapeutic targets in elderly lung cancer patients with an history of smoking and elevated monocyte counts.
Keywords: Immunoglobulin E, lung cancer, Clinical features, Immunotherapy, biomarker
Received: 29 May 2025; Accepted: 04 Jul 2025.
Copyright: © 2025 Zhou, Liu, Zhang, Kang, Kang, Meng and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaonan Wang, The First Affiliated Hospital of China Medical University, Shenyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.